Effect of an oil-free hydroethanolic pumpkin seed extract on symptoms of benign prostatic hyperplasia

2019 ◽  
Author(s):  
M Leibbrand ◽  
S Siefer ◽  
C Schön ◽  
T Perrinjaquet-Moccetti ◽  
A Kompek ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Seed Extract ◽  
Prostatic Hyperplasia ◽  
Pumpkin Seed

scholarly journals Effects of Pumpkin Seed in Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia in the One-Year, Randomized, Placebo-Controlled GRANU Study

2014 ◽  
Vol 94 (3) ◽  
pp. 286-295 ◽  
Author(s):  
Winfried Vahlensieck ◽  
Christoph Theurer ◽  
Edith Pfitzer ◽  
Brigitte Patz ◽  
Norbert Banik ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Benign Prostatic Hyperplasia ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Seed Extract ◽  
Prostatic Hyperplasia ◽  
Secondary Outcome ◽  
Pumpkin Seed ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Introduction: The German Research Activities on Natural Urologicals (GRANU) study was a randomized, partially blinded, placebo-controlled, parallel-group trial that investigated the efficacy of pumpkin seed in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS). Subjects and Methods: A total of 1,431 men (50−80 years) with BPH/LUTS were randomly assigned to either pumpkin seed (5 g b.i.d.), capsules with pumpkin seed extract (500 mg b.i.d.) or matching placebo. The primary response criterion was a decrease in International Prostate Symptom Score (IPSS) of ≥5 points from baseline after 12 months. Secondary outcome measures included IPSS-related quality of life, IPSS single items and diary-recorded nocturia. Results: After 12 months, the response rate (intention-to-treat/last-observation-carried-forward approach) did not differ between pumpkin seed extract and placebo. In the case of pumpkin seed (responders: 58.5%), the difference compared with placebo (responders: 47.3%) was descriptively significant. The study products were well tolerated. Overall, in men with BPH, 12 months of treatment with pumpkin seed led to a clinically relevant reduction in IPSS compared with placebo. Conclusion: In order to fully justify a recommendation for the use of pumpkin seed to treat moderate LUTS, these findings need to be substantiated in a confirmatory study or systematic review.

scholarly journals Effects of an Oil-Free Hydroethanolic Pumpkin Seed Extract on Symptom Frequency and Severity in Men with Benign Prostatic Hyperplasia: A Pilot Study in Humans

2019 ◽  
Vol 22 (6) ◽  
pp. 551-559 ◽  
Author(s):  
Martin Leibbrand ◽  
Simone Siefer ◽  
Christiane Schön ◽  
Tania Perrinjaquet-Moccetti ◽  
Albert Kompek ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Pilot Study ◽  
Seed Extract ◽  
Prostatic Hyperplasia ◽  
Pumpkin Seed ◽  
Symptom Frequency

scholarly journals Evaluation of Juniperus communis L. seed extract on benign prostatic hyperplasia induced in male Wistar rats

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Fatemeh Akbari ◽  
Mohammad Azadbakht ◽  
Kanu Megha ◽  
Ayat Dashti ◽  
Lale Vahedi ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Wistar Rats ◽  
Histopathological Examination ◽  
Seed Extract ◽  
Prostatic Hyperplasia ◽  
Vehicle Group ◽  
Common Disease ◽  
Therapeutic Effects ◽  
Juniperus Communis ◽  
Male Wistar Rats

Abstract Background Benign prostatic hyperplasia (BPH) is a common disease which causes various health problems for elderly men such as urinary retention, recurring urinary tract infection and bladder stones. The aim of this study is to evaluate the therapeutic effects of Juniperus communis L. seed extract (JCS) on BPH in male Wistar rats. Methods To this end, 30 rats were divided into 5 groups (N = 6): group 1 (vehicle), group 2 (disease control), group 3 (standard medicine; 10 mg/kg finasteride), and groups 4 and 5 were treated with 300 mg/kg and 600 mg/kg of the hydroalcoholic JCS seed extract, respectively. Groups 2, 3, 4 and 5 received testosterone enanthate to induce prostatic hyperplasia. At the end of experimental period (28 days), prostate glands were cut off under anesthesia. Histopathological examination was done and biochemical parameters such as Malondialdehyde, Glutathione and protein carbonyl were also measured. Their body weights were also observed during the study. At the end of the experiment, prostate weights and prostate specific antigen (PSA) levels were measured. Prostate index, inhibition prostate weight and inhibition prostate index were also calculated. Results Both histopathological examination and biochemical parameter results showed significant improvements in rats treated with finasteride and 600 mg/kg JCS extract (p < 0.01). In addition, PSA levels showed significant decrease in comparison with the disease group. But acute toxicity test indicated that using JCS extract resulted in an increase in liver enzymes (ALP, LDH, SGOT, SGPT). As a result, the extract should be used with caution. Conclusions Oral administration of JCS extract is effective on preventing testosterone-induced benign prostatic hyperplasia.

scholarly journals Treatment of Benign Prostatic Hyperplasia by Natural Drugs

Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7141
Author(s):  
Eszter Csikós ◽  
Adrienn Horváth ◽  
Kamilla Ács ◽  
Nóra Papp ◽  
Viktória Lilla Balázs ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Pumpkin Seed ◽  
Prostate Cell ◽  
Safety Issues ◽  
Advantages And Disadvantages ◽  
Estrogen Activity ◽  
Surgical Options ◽  
Natural Drugs ◽  
Preclinical And Clinical Studies

Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the above-mentioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.

scholarly journals Phytosterols in hull-less pumpkin seed oil, rich in Δ7-phytosterols, ameliorate benign prostatic hyperplasia by lowing 5α-reductase and regulating balance between cell proliferation and apoptosis in rats

2021 ◽  
Author(s):  
Xin-cong Kang ◽  
Tian Chen ◽  
Jia-li Zhou ◽  
Peng-yuan Shen ◽  
Si-hui Dai ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Growth Factor ◽  
Seed Oil ◽  
Quantitative Polymerase Chain Reaction ◽  
Prostatic Hyperplasia ◽  
Common Disease ◽  
Preparative Hplc ◽  
Active Components ◽  
Pumpkin Seed ◽  
Pumpkin Seed Oil

Background: Pumpkin seed oil is widely used to treat benign prostatic hyperplasia (BPH), a common disease in elder men. However, its active components and mechanism have remained to be elucidated. Objective: The objective of the present study was to investigate the active components of pumpkin seed oil and its mechanism against BPH. Design: Total phytosterol (TPS) was isolated from hull-less pumpkin (Cucurbita pepo L. var. Styriaca) seed oil and analyzed by gas chromatography/mass spectrometry (GC/MS). Three phytosterols were purified by preparative HPLC (high performance liquid chromatography) and confirmed by NMR (nuclear magnetic resonance). TPS (3.3 mg/kg body weight, 1 mL/day/rat) was administered intragastrically to the testosterone propionate-induced BPH rats for 4 weeks. The structure changes of prostate tissues were assessed by hematoxylin & eosin (H&E) staining. The expression of androgen receptor (AR) and steroid receptor coactivator 1 (SRC-1) was analyzed by immunohistochemistry, while that of 5α-reductase (5AR), apoptosis, or proliferation-related growth factors/proteins was detected by real-time quantitative polymerase chain reaction or western blotting. Results: The ∆7-phytosterols in TPS reached up to 87.64%. Among them, 24β-ethylcholesta-7,22,25-trienol, 24β-ethylcholesta-7,25(27)-dien-3-ol, and ∆7-avenasterol were confirmed by NMR. TPS treatment significantly ameliorated the pathological prostate enlargement and restored histopathological alterations of prostate in BPH rats. It effectively suppressed the expressions of 5AR, AR, and coactivator SRC-1. TPS inhibited the expression of proliferation-related growth factor epidermal growth factor, whereas it increased the expressions of apoptosis-related growth factor/gene transforming growth factor-β1. The proliferation-inhibiting effect was achieved by decreasing the ERK (extracellular signal-regulated kinase) phosphorylation, while apoptosis was induced by Caspase 3 activation through JNK (c-Jun N-terminal kinase) and p38 phosphorylation. Conclusion: TPS from hull-less pumpkin seed oil, with ∆7-phytosterols as its main ingredients, is a potential nutraceutical for BPH prevention.

scholarly journals Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation

Pharmaceutics ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 640 ◽  
Author(s):  
Nabil A. Alhakamy ◽  
Usama A. Fahmy ◽  
Osama A. A. Ahmed
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Zeta Potential ◽  
Seed Oil ◽  
Prostatic Hyperplasia ◽  
Pharmacokinetic Data ◽  
Pumpkin Seed ◽  
Prostate Weight ◽  
Globule Size ◽  
Pumpkin Seed Oil

The FDA has approved tadalafil (TDL) for the treatment of benign prostatic hyperplasia (BPH)-associated symptoms. Pumpkin seed oil (PSO) has shown promise for the relief of prostatitis-related lower urinary tract symptoms. The aim was to improve TDL delivery to the prostate and assess the combined effect of TDL with a PSO-based formula in the management of BPH. PSO, Tween 80, and polyethylene glycol 200 were selected for the optimization of self nano-emulsified drug delivery system (SNEDDS). The formed vesicles were assessed for their globule size and zeta potential. A rat in vivo study was carried out to investigate prostate weight and index, histopathology, and pharmacokinetics. The average globule size for the optimized TDL-PSO SNEDDS was 204.8 ± 18.76 nm, with a zeta-potential value of 7.86 ± 1.21 mV. TDL-PSO SNEDDS produced a marked drop in prostate weight by 35.51% and prostate index by 36.71% compared to the testosterone-only group. Pharmacokinetic data revealed a 2.3-fold increase of TDL concentration, from optimized TDL-PSO SNEDDS, in the prostate compared with the raw TDL group. This study indicated that the combination of TDL and PSO in an optimized TDL PSO SNEDDS formula improved the efficacy of TDL in the management of BPH.

Sign in / Sign up

Export Citation Format

Share Document